Figure 1.
Impact of immune-related adverse events (irAEs) on progression-free survival (PFS). PFS, progression-free survival; CI, confidence interval; irAE, immune-related adverse events; P-values <0.05 were considered statistically significant.
Impact of immune-related adverse events (irAEs) on progression-free survival (PFS). PFS, progression-free survival; CI, confidence interval; irAE, immune-related adverse events; P-values <0.05 were considered statistically significant.